**Arthritis Profile M** is a comprehensive diagnostic blood panel designed to evaluate joint pain, inflammation, and potential autoimmune disorders. It aids in detecting and managing conditions such as rheumatoid arthritis, gout, osteoarthritis, and other musculoskeletal inflammatory diseases.
This profile typically measures key biomarkers, including Rheumatoid Factor (RF), Anti-CCP, C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Uric Acid, Calcium, and Complete Blood Count (CBC). Together, these tests help identify active systemic inflammation, assess bone health, rule out underlying autoimmune responses, and differentiate specific joint pathologies.
Early testing allows clinicians to deliver targeted treatment, preserve joint mobility, and prevent long-term joint damage.

An **arthritis scan test** is a non-invasive diagnostic imaging procedure—such as an MRI, ultrasound, X-ray, or CT scan—used to evaluate joint health and detect structural changes. It provides detailed visual insights into affected joints, allowing clinicians to assess cartilage wear, bone erosion, joint space narrowing, fluid accumulation, and soft tissue inflammation.
By accurately identifying conditions like osteoarthritis, rheumatoid arthritis, or psoriatic arthritis, these scans play a critical role in confirming diagnoses. They also help monitor disease progression and evaluate treatment response over time. Timely imaging empowers healthcare providers to customize targeted therapies, protect joint functionality, and manage long-term discomfort effectively.

An **Arthritis Screen Profile (4 Markers)** is a targeted, focused diagnostic blood test designed for early evaluation of joint pain and systemic inflammation. By measuring four key biomarkers—typically **Rheumatoid Factor (RF)**, **Anti-CCP**, **C-Reactive Protein (CRP)**, and **Erythrocyte Sedimentation Rate (ESR)**—this profile helps clinicians differentiate between autoimmune disorders like rheumatoid arthritis and non-autoimmune conditions.
The test detects active inflammatory processes, identifies specific autoantibodies, and assesses overall disease severity. Swift and precise, the 4-marker panel enables healthcare providers to establish an accurate diagnosis, start timely therapeutic intervention, and help safeguard long-term joint health and mobility.